Fennec Pharmaceuticals (FENC) Expected to Announce Quarterly Earnings on Tuesday

Fennec Pharmaceuticals (NASDAQ:FENC) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $8.18 million for the quarter.

Fennec Pharmaceuticals Trading Down 3.7 %

Fennec Pharmaceuticals stock opened at $5.97 on Friday. The firm has a market capitalization of $164.74 million, a P/E ratio of -59.69 and a beta of 0.32. The business has a 50-day moving average of $5.92 and a 200-day moving average of $5.87. Fennec Pharmaceuticals has a 1 year low of $3.96 and a 1 year high of $10.07.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a report on Tuesday, March 11th. Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a report on Monday, March 10th.

Insiders Place Their Bets

In related news, Director Rosty Raykov sold 10,000 shares of the stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $5.25, for a total transaction of $52,500.00. Following the sale, the director now owns 61,156 shares of the company’s stock, valued at $321,069. This represents a 14.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 31,186 shares of company stock worth $191,589 in the last 90 days. Company insiders own 11.76% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.